Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$130 Mln
Revenue (TTM)
$60 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
14.9
P/B Ratio
5
Industry P/E
--
EV/EBITDA
0.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$1
EPS
$0.1
Face value
--
Shares outstanding
57,891,493
CFO
$-358.27 Mln
EBITDA
$-357.80 Mln
Net Profit
$-377.62 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| 4.3 | 12.0 | 4.3 | 250.1 | 18.8 | -29.8 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| 126.2 | -29.7 | -15.0 | -89.2 | -17.4 | 101.7 | 56.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
|
2.4 | 129.7 | 59.6 | 8.6 | -24.4 | 16.3 | 14.9 | 5.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates... include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 Read more
Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Spero Therapeutics Inc (SPRO) is $2.43 (NASDAQ) as of 02-Apr-2026 17:49 EDT. Spero Therapeutics Inc (SPRO) has given a return of 18.78% in the last 3 years.
The P/E ratio of Spero Therapeutics Inc (SPRO) is 14.93 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.14
|
2.34
|
|
2024
|
-0.81
|
1.21
|
|
2023
|
3.42
|
0.73
|
|
2022
|
-1.82
|
1.11
|
|
2021
|
-5.73
|
5.83
|
The 52-week high and low of Spero Therapeutics Inc (SPRO) are Rs 3.22 and Rs 0.51 as of 04-Apr-2026.
Spero Therapeutics Inc (SPRO) has a market capitalisation of $ 130 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Spero Therapeutics Inc (SPRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.